Guo Jian, de Waard Vivian, Van Eck Miranda, Hildebrand Reeni B, van Wanrooij Eva J A, Kuiper Johan, Maeda Nobuyo, Benson G Martin, Groot Pieter H E, Van Berkel Theo J C
Division of Biopharmaceutics, Gorlaeus Laboratories, Leiden University, Leiden, The Netherlands.
Arterioscler Thromb Vasc Biol. 2005 May;25(5):1014-9. doi: 10.1161/01.ATV.0000163181.40896.42. Epub 2005 Mar 17.
Using bone marrow transplantation, we have previously demonstrated the critical role that hematopoietic CCR2 plays in early atherogenesis. Reconstitution of irradiated apolipoprotein (apo) E3-Leiden mice with CCR2-deficient bone marrow progenitor cells resulted in 86% reduction on overall atherosclerotic lesion development. However, no data on CCR2 in the cause of established atherosclerosis have been reported so far.
To study the role of CCR2 in established atherosclerotic lesions, bone marrow progenitor cells harvested from apoE-/- and apoE-/-/CCR2-/- mice were transplanted into lethally irradiated 16-week-old apoE-/- mice with established atherosclerotic lesions. No significant differences were found in serum total cholesterol and triglycerides levels at different time points after transplantation. At age 16 weeks, lesion size in control apoE-/- mice was 3.28+/-1.06x10(5) microm2. At 9 weeks after transplantation, apoE-/---> apoE-/- and apoE-/-/CCR2-/---> apoE-/- mice had developed significantly larger atherosclerotic lesions (4.49+/-0.92x10(5) microm2, P<0.02 and 4.15+/-0.62x10(5) microm2, P<0.04 compared with controls, respectively). However, no significant effect of disruption of hematopoietic CCR2 was observed on the progression of lesions. Furthermore, the macrophage positive area (78+/-4% versus 72+/-9%) and collagen content (11+/-6% versus 15+/-3%) of the lesions were similar as well.
In contrast to the critical role of CCR2 in the initiation of atherogenesis, bone marrow progenitor cell-derived CCR2 does not influence the progression of established atherosclerotic lesions, pointing to additional mechanisms for recruitment of monocytes at later stages of lesion development.
我们之前通过骨髓移植证明了造血CCR2在早期动脉粥样硬化形成中起关键作用。用CCR2缺陷的骨髓祖细胞重建经辐射的载脂蛋白(apo)E3-莱顿小鼠,可使总体动脉粥样硬化病变发展减少86%。然而,目前尚无关于CCR2在已形成动脉粥样硬化病因方面的数据报道。
为研究CCR2在已形成的动脉粥样硬化病变中的作用,将从apoE-/-和apoE-/-/CCR2-/-小鼠采集的骨髓祖细胞移植到经致死剂量照射且已形成动脉粥样硬化病变的16周龄apoE-/-小鼠体内。移植后不同时间点的血清总胆固醇和甘油三酯水平无显著差异。16周龄时,对照apoE-/-小鼠的病变大小为3.28±1.06x10(5) 平方微米。移植后9周时,apoE-/-→apoE-/-和apoE-/-/CCR2-/-→apoE-/-小鼠形成的动脉粥样硬化病变明显更大(分别为4.49±0.92x10(5) 平方微米,P<0.02;4.15±0.62x10(5) 平方微米,P<0.04,与对照组相比)。然而,未观察到造血CCR2缺失对病变进展有显著影响。此外,病变的巨噬细胞阳性面积(78±4%对72±9%)和胶原含量(11±6%对15±3%)也相似。
与CCR2在动脉粥样硬化起始中的关键作用相反,骨髓祖细胞来源的CCR2并不影响已形成的动脉粥样硬化病变的进展,这表明在病变发展后期单核细胞募集存在其他机制。